Nicole J Tarlton1, Charles Moritz2, Sheila Adams-Sapper2, Lee W Riley2. 1. School of Public Health, Division of Infectious Diseases and Vaccinology, University of California, Berkeley, CA, USA. Electronic address: nicole_tarlton@berkeley.edu. 2. School of Public Health, Division of Infectious Diseases and Vaccinology, University of California, Berkeley, CA, USA.
Abstract
OBJECTIVES: To determine the contribution of specific uropathogenic Escherichia coli (UPEC) lineages, drug resistance genes, and plasmid incompatibility/replicon (Inc) groups to the prevalence of β-lactam-resistant urinary tract infections (UTIs) in a university community. METHODS: Urine samples were consecutively collected and cultured over a 2-year period from patients presenting to a university health centre with symptoms of UTI. Isolated UPEC were subtyped by multilocus sequence typing and fimH typing, and tested by PCR and sequencing for β-lactamase genes and plasmid Inc groups. RESULTS: Among 273 UPEC isolates, 85 (31%) were ampicillin-resistant (AMP-R) and 188 (69%) were susceptible to all β-lactam drugs (AMP-S). Six lineages accounted for two-thirds of the isolates: ST95 (21%), ST69 (11%), ST420 (11%), ST73 (10%), ST127 (8%), and ST404 (3%). ST69 and ST404 were associated with AMP-R (P=0.003, P=0.0005), while ST420 and ST127 were associated with AMP-S (P<0.0001, P=0.027). ST95 contained four fimH types; the ST95/f-6 sublineage was more frequently identified among the AMP-R population (P = 0.009), while the ST95/f-47 sublineage was more frequently identified among the AMP-S population (P=0.007). The most common β-lactamase gene was blaTEM, which was identified in 81 (95%) AMP-R isolates. IncFIB, IncFIA, and IncB/O type plasmids were the most commonly identified types, and were associated with β-lactam resistance (P<0.001 for all). CONCLUSIONS: These observations indicate that the prevalence of β-lactam-resistant UTIs in this community was largely determined by a limited set of circulating UPEC STs and sublineages, carrying TEM β-lactamase genes that were likely encoded on one of three Inc type plasmids.
OBJECTIVES: To determine the contribution of specific uropathogenic Escherichia coli (UPEC) lineages, drug resistance genes, and plasmid incompatibility/replicon (Inc) groups to the prevalence of β-lactam-resistant urinary tract infections (UTIs) in a university community. METHODS: Urine samples were consecutively collected and cultured over a 2-year period from patients presenting to a university health centre with symptoms of UTI. Isolated UPEC were subtyped by multilocus sequence typing and fimH typing, and tested by PCR and sequencing for β-lactamase genes and plasmid Inc groups. RESULTS: Among 273 UPEC isolates, 85 (31%) were ampicillin-resistant (AMP-R) and 188 (69%) were susceptible to all β-lactam drugs (AMP-S). Six lineages accounted for two-thirds of the isolates: ST95 (21%), ST69 (11%), ST420 (11%), ST73 (10%), ST127 (8%), and ST404 (3%). ST69 and ST404 were associated with AMP-R (P=0.003, P=0.0005), while ST420 and ST127 were associated with AMP-S (P<0.0001, P=0.027). ST95 contained four fimH types; the ST95/f-6 sublineage was more frequently identified among the AMP-R population (P = 0.009), while the ST95/f-47 sublineage was more frequently identified among the AMP-S population (P=0.007). The most common β-lactamase gene was blaTEM, which was identified in 81 (95%) AMP-R isolates. IncFIB, IncFIA, and IncB/O type plasmids were the most commonly identified types, and were associated with β-lactam resistance (P<0.001 for all). CONCLUSIONS: These observations indicate that the prevalence of β-lactam-resistant UTIs in this community was largely determined by a limited set of circulating UPEC STs and sublineages, carrying TEM β-lactamase genes that were likely encoded on one of three Inc type plasmids.
Authors: James R Johnson; Veronika Tchesnokova; Brian Johnston; Connie Clabots; Pacita L Roberts; Mariya Billig; Kim Riddell; Peggy Rogers; Xuan Qin; Susan Butler-Wu; Lance B Price; Maliha Aziz; Marie-Hélène Nicolas-Chanoine; Chitrita Debroy; Ari Robicsek; Glen Hansen; Carl Urban; Joanne Platell; Darren J Trott; George Zhanel; Scott J Weissman; Brad T Cookson; Ferric C Fang; Ajit P Limaye; Delia Scholes; Sujay Chattopadhyay; David C Hooper; Evgeni V Sokurenko Journal: J Infect Dis Date: 2013-01-03 Impact factor: 5.226
Authors: Magdalena T Nüesch-Inderbinen; Melinda Baschera; Katrin Zurfluh; Herbert Hächler; Hansjakob Nüesch; Roger Stephan Journal: Front Microbiol Date: 2017-12-01 Impact factor: 5.640
Authors: David M Gordon; Sarah Geyik; Olivier Clermont; Claire L O'Brien; Shiwei Huang; Charmalie Abayasekara; Ashwin Rajesh; Karina Kennedy; Peter Collignon; Paul Pavli; Christophe Rodriguez; Brian D Johnston; James R Johnson; Jean-Winoc Decousser; Erick Denamur Journal: mSphere Date: 2017-05-31 Impact factor: 4.389
Authors: Nicole J Tarlton; Danka-Florence Petrovic; Bradley W Frazee; Clarissa A Borges; Emily M Pham; Aubrianne K Milton; Nicole Jackson; Tara R deBoer; Niren Murthy; Lee W Riley Journal: Microb Drug Resist Date: 2020-08-19 Impact factor: 3.431
Authors: Anette M Hammerum; Lone Jannok Porsbo; Frank Hansen; Louise Roer; Hülya Kaya; Anna Henius; Karina Lauenborg Møller; Ulrik S Justesen; Lillian Søes; Bent L Røder; Philip K Thomsen; Mikala Wang; Turid Snekloth Søndergaard; Barbara Juliane Holzknecht; Claus Østergaard; Anne Kjerulf; Brian Kristensen; Henrik Hasman Journal: Euro Surveill Date: 2020-05
Authors: Matej Medvecky; Costas C Papagiannitsis; Ethan R Wyrsch; Ibrahim Bitar; Max L Cummins; Steven P Djordjevic; Monika Dolejska Journal: mSphere Date: 2022-07-05 Impact factor: 5.029